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GFI1 downregulation promotes inflammation-linked
metastasis of colorectal cancer
Wenjing Xing1,2,7, Yun Xiao3,7, Xinliang Lu1,2,4, Hongyan Zhu1,2, Xiangchuan He1,2, Wei Huang1,2, Elsa S Lopez5, Jerry Wong5,
Huanyu Ju1,2, Linlu Tian1,2, Fengmin Zhang2, Hongwei Xu1,2, Sheng Dian Wang4, Xia Li*,3, Michael Karin*,5 and Huan Ren*,1,2,6
Inflammation is frequently associated with initiation, progression, and metastasis of colorectal cancer (CRC). Here, we unveil a
CRC-specific metastatic programme that is triggered via the transcriptional repressor, GFI1. Using data from a large cohort of
clinical samples including inflammatory bowel disease and CRC, and a cellular model of CRC progression mediated by cross-talk
between the cancer cell and the inflammatory microenvironment, we identified GFI1 as a gating regulator responsible for a
constitutively activated signalling circuit that renders CRC cells competent for metastatic spread. Further analysis of mouse
models with metastatic CRC and human clinical specimens reinforced the influence of GFI1 downregulation in promoting CRC
metastatic spread. The novel role of GFI1 is uncovered for the first time in a human solid tumour such as CRC. Our results imply
that GFI1 is a potential therapeutic target for interfering with inflammation-induced CRC progression and spread.
Cell Death and Differentiation (2017) 24, 929–943; doi:10.1038/cdd.2017.50; published online 7 April 2017
Chronic inflammation is an important risk factor for colorectal
cancer (CRC) development and progression.1–3 Colitis-
associated CRC shows more rapid progression, lower
sensitivity to treatment and higher mortality than sporadic
CRC.4 The tumour microenvironment contains cytokines,
chemokines, inflammatory mediators, and so on, which have
critical roles in almost every stage of progression to
malignancy and metastasis.5–11 Approximately 50% of CRC
patients develop metastatic disease, and only a minority of
patients who undergo resection of metastases attain long-
term survival.12
CRC progression to metastatic disease is a multi-step
process involving extensive tumour–stroma cross-talk. Potent
metastasis-promoting factors, including cytokines and extra-
cellular matrix (ECM) proteins,may trigger epithelial mesench-
ymal transition (EMT), which drives cancer cell dissemination.
ECM-degrading proteases and the c-MET, Notch, and TGFβ
signalling pathways regulate tumour–stroma interactions and
metastasis.13–15 Among these, TGFβ signalling is essential for
the metastasis of CRC cells. Mice treated with a TGFβR1
inhibitor were resilient to metastasis formation.15 Within the
tumour microenvironment, amplified cyclo-oxygenase (COX)-
converted prostaglandin E2 (PGE2) further induces the
secretion of IL6, IL8, VEGF, iNOS, MMP-2, and MMP-9,
leading to increased tumour invasion and metastasis.16 PGE2
exerts its effect by binding to EP receptors. Recent studies
have shown that PGE2–EP2 signalling in tumour-infiltrating
neutrophils promotes CRC cell growth via amplifying inflam-
mation and shaping the tumour microenvironment.17,18 More-
over, tumour-associated macrophages (TAMs) are a major
component promoting cancer progression in many aspects.
The association between high TAMs and poor prognosis is
observed in CRC.6 Nevertheless, tumour–stroma cross-talk
during metastatic progression is highly complex, and the
signalling events that control metastasis may be stage-
specific. Eventually, potent microenvironmental factors may
initiate a programme in which responsive cancer cells are
selected as metastatic initiators that may travel to a secondary
site and establish metastatic growth.19
Transcription factors (TF) have key roles in determining cell
fate and behaviour. Given a significant link between inflam-
matory bowel disease (IBD) and CRC,20 we aimed to define
key TF-regulated networks that may mediate transition
programmes during CRC progression by analysing data sets
from a large cohort of clinical specimens (Supplementary
Figure S1).21 We thus defined a 24-core TF-regulated network
comprising inflammation- and/or CRC-related genes.21 To
validate the TF network in a cellular model, we applied an
inflammation-promoting culture medium,22 LSMCM (LPS-
stimulated Monocyte Conditioned Medium), derived from
human THP1 cells, to a series of CRC cell lines
(Supplementary Figure S2A). LSMCM exposure triggered
changes in CRC cell behaviour, including the EMT, and greatly
increased cell migration and invasion.21 The expression of two
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TFs, including GFI1 (Growth factor independence 1) and
STAT3, was significantly altered after LSMCM application
(Supplementary Figure S1B and Table 1).
GFI1 is a six-zinc-finger transcription repressor belonging to
the SNAG domain family.23 GFI1 has primarily been examined
for its roles in different haematopoietic compartments,24,25 cell
cycle regulation,23 and haematopoiesis.26–29 Outside of the
haematopoietic system, GFI1 is involved in lineage decisions
during intestinal epithelial cell (IEC) differentiation.30,31 Until
recently, however, it is not known whether GFI1 contributes to
CRC development and progression. Here, we described
the establishment of a constitutively activated feed-forward
inflammatory signalling circuit normally harnessed through
GFI1 during CRC progression. This circuit has crucial roles in
promoting CRC metastatic spread.
Results
Monocyte-derived TGFβ induces inflammation-linked
CRC cell metastatic behaviours. We generated a pre-
viously established cellular model using LSMCM culture
medium conditioned by LPS-stimulated monocytes (Supple-
mentary Figure S2A).21,22 Four (HT29, LoVo, HCT116, and
SW480) of the five CRC cell lines (including SW620) actively
responded to LSMCM, morphologically changing into spindle-
shaped fibroblast-like cells (Figure 1a). Further examination
revealed that LSMCM greatly induced EMTand increased cell
migration and invasion in responsive cells (Figure 1b–i and
Supplementary Figure S2B); however, SW620 cells were the
least responsive to LSMCM (Figure 1j and k), in which remnant
LPS had a minor effect (Supplementary Figure S2C). More-
over, the conditioned medium derived from LPS-stimulated
macrophages differentiated from human peripheral blood
mononuclear cells (PBMCs), or the U-937 human monocyte
cell line significantly induced EMTand increased cell migration
and invasion in HT29 cells (Supplementary Figure S2D–F).
These supplementary models provided proof of concept on the
cellular model system to study the effect of TAMs and the
tumour microenvironment in vitro.
To understand how LSMCM elicited these phenotypic
changes, we analysed the supernatants of LSMCM-
stimulated HT29 cells on 40 selected cytokines highly relevant
to activated macrophages.32 The results indicated that the
concentrations of TGFβ1, IL1α, IFNγ, I309 (CCL1), and TNFβ
were significantly decreased within the first 6 h of treatment
and subsequently returned to levels equivalent to those
present in the original LMSCM after 24 h of incubation,
whereas GM-CSF, IL8, MCP1, PDGFBB, and sTNFR1
remained elevated for up to 24 h (Figure 2a). These data
suggested that HT29 cells may consume or degrade certain
cytokines in the medium before secreting these cytokines;
these cells rapidly produced additional GM-CSF and IL8.
To identify the most important factors in LSMCM-affecting
CRC cell behaviour, we referred to a previously identified core
TF network linking IBD and CRC (Supplementary
Figure S1).21 Among the 24-core TFs and their regulated
network in LSMCM-stimulated HT29 cells, two genes,
TGFBR2 and TLR8, were significantly upregulated (Table 1).
Consistently, TGFBR2 mRNA expression increased upon
LSMCM addition (Supplementary Figure S3A). Furthermore,
the application of anti-TGFβ-neutralising antibodies prior to
LMSCM significantly blunted EMT-related behavioural
changes and migration/invasion in CRC cells (Figure 2b
and c and Supplementary Figure S3B, S3C). Thus, TGFβ
signalling may be an important contributor to the observed
changes in CRC cell behaviour.
Inflammation-linked changes in CRC cell behaviour
resulting from multiple factors in the cell model system.
CRC cells exhibited maximal behavioural changes after
treatment for 24 h with LSMCM. To investigate the factors
driving these changes, we examined the expression of
multiple effectors in HT29 cells for up to 96 h. The
expressions of GFI1 and STAT3 were significantly altered
upon LSMCM treatment, and the GFI1-associated factors
PTGER2 (coding for EP2), TGFBR2, and STAT3-associated
AKT1 were upregulated (Table 1). In addition, we examined
ERK1/2, NF-κB (p65 subunit), EMT-related Snail, Zeb1, and
Twist in the expression analysis, considering their effects on
inflammation and metastasis.33,34 We observed sequential
changes in the expression or activities of almost all of these
effectors for up to 96 h at the protein level (Figure 2d and
Supplementary Figure S3D). Two of the earliest changes
were decreased GFI1 and increased ERK phosphorylation.
Moreover, the expression of the GFI1-repressed gene
PTGER2 expectedly increased upon LSMCM addition
(Figure 2e). Other changes subsequently occurred, including
the activation of STAT3, EP2, AKT, and p65 (Figure 2d);
Table 1 Differential expression of varied genes at the mRNA level in HT29 cell
model
Gene Fold changea Gene Fold changea
GFI1b −2.58 BUB1B 1.32
TGFBR2 2.19 TLR8 2.19
TCF7L2 1.32 RUNX3b −1.14
REG4 1.09 CD40 −1.24
HDAC5 1.15 CXCR4 −1.15
SMAD2 1.21 HDAC5 −1.09
MUC2 1.34 CXCL13 −1.32
PTGER2 4.80 CCR7 −1.17
TCF7L2b −1.00 SMAD2b 1.44
RPS9 −1.02 SOX10b 1.04
APC −1.12 TFF3b 1.37
PTPRH −1.20 SMAD7b 1.16
ARHGEF4 −1.06 ETS1b 1.12
NAT1 −1.18 POU5F1Bb −1.61
STAT3b 2.58 FOXO1b −1.41
AKT1 3.58 HOXA4b −1.30
TP53I3 2.58 NFYBb −1.05
XBP1b −1.60 FOXC1b −1.20
C5 −1.42 ZNF589b 1.07
CCL24 −1.06 TCF4b 1.12
CHST2 −1.20 SREBFb −1.13
IL1B −1.16 CEBPGb 1.16
PBX1b 1.80 NFATC1b −1.07
IL23R 1.14 PROM1b 1.05
COX1 1.21 BACH2b −1.26
TYMS 1.64 POU2F2b 1.02
aCells were treated with LSMCM for 24 h. Gene expression showing at least
twofold change was recognised in red as being significantly altered. Consistent
results from independent real-time PCR assays were obtained. bTranscriptional
factor, others are their related genes. The bold entries indicate the transcrip-
tional factors
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Figure 1 LSMCM increases CRC cell metastatic behaviour. (a) Culture with LSMCM induces morphology changes in HT29, LoVo, HCT116, SW480, and SW620 cells. (b)
qRT-PCR of E-cadherin, Fibronectin, and Vimentin mRNA in HT29 with LSMCM for different times or prepared from supernatant of THP1 cells that were incubated with different
LPS concentrations. (c) HT29 cells were treated with LSMCM for different times; or prepared from supernatant of THP1 cells that were incubated with different LPS
concentrations. Cell migratory and invasive activities were measured and quantified. (d) LoVo cells were treated as in (c) and their migratory and invasive activity was measured
and quantified. (e) qRT-PCR of E-cadherin, Fibronectin and Vimentin mRNA in LoVo cells treated as in (b). Results of similar experiments were exhibited for HCT116
cells, SW480 cells and SW620 cells, respectively, in (f–k). (b–k) show means± S.D. of three independent experiments. Statistically significant differences are indicated.
*Po0.05; **Po0.01
GFI1 suppresses colorectal cancer metastasis
W Xing et al
931
Cell Death and Differentiation
Figure 2 Monocyte-derived TGFβ downregulates GFI1 and induces EMTand cell metastatic behaviour. (a) Cytokines in culture medium from HT29 cells treated with LSMCM
for 6 or 24 h were measured by Cytokine antibody arrays. Results shown are fold changes compared with freshly collected LSMCM. (b) qRT-PCR of E-cadherin, Fibronectin, and
Vimentin mRNA in HT29 cells treated with LSMCM with/without anti-TGFβ-neutralising antibodies for 24 h. (c) Quantification of data shown in Supplementary Figure S3B,
depicting the role of TGFβ in LSMCM-induced changes in cell behaviour. (d) HT29 cells were incubated with LSMCM for up to 96 h. Whole-cell lysates were prepared at the
indicated time points and analysed for expression and phosphorylation of the indicated proteins. (e) Time course of GFI1 and PTGER2 mRNA expression in HT29 cells
treated with LSMCM by qRT-PCR. (f) Effect of anti-TGFβ-neutralising antibodies on LSMCM-induced suppression of GFI1 expression. (g) qRT-PCR of GFI1 mRNA in HT29 cells
treated with LSMCM plus indicated concentrations of anti-TGFβ-neutralising antibodies. (h) HT29 cells were treated with LSMCM for up to 96 h, and the expression or
phosphorylation of SMAD2/3/4 were analysed. (i) qRT-PCR of SMAD2, SMAD3, SMAD4, SMAD7, and RPS6KB1 mRNA in HT29 cells treated with LSMCM or LSMCM
plus 2.5 μg/μl anti-TGFβ neutralising antibodies. (b), (c), (e), (g), (i) show means± S.D. of three independent experiments. Statistically significant differences are indicated.
*Po 0.05; **Po 0.01; ***Po 0.001
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increased expressions of Snail and Zeb1, but not Twist
(Supplementary Figure S3D).
Significantly, the LSMCM-induced GFI1 decrease was
reversed by TGFβ neutralisation in a dose-dependent manner
in HT29 cells (Figure 2f and g). Further assays indicated that
TGFβ might exert this effect via SMAD-dependent pathways.
Notably, phospho-SMAD3 was significantly elevated as early
as 6 h and remained activated for 96 h; phospho-SMAD2 and
the expression of SMAD4 were also elevated (Figure 2h).
Conversely, TGFβ neutralisation reversed the LSMCM-
mediated SMAD3 elevation (Figure 2i). Notably, the expres-
sion of RPS6KB1, a factor in SMAD-independent pathways,
was unaffected by either LSMCM or additional TGFβ
neutralisation (Figure 2i). Furthermore, in the supernatant,
three other cytokines, IL1α, TNFβ, and IFNγ, whose expres-
sion changes were similar to those of TGFβ under LSMCM
treatment (Figure 2a), led to GFI1 downregulation and the
activation of cellular downstream effectors to varied extents
(Supplementary Figure S3E–G). Collectively, these results
showed that effects of multiple factors contributed to the
transformation of CRC cells under LSMCM treatment.
GFI1 is a gating regulator in the cellular transformation of
CRC cells. We next examined whether decreased GFI1
expression affected the aforementioned changes in HT29
cells. Forced GFI1 expression decreased PTGER2 (gene
name for EP2) mRNA (Figure 3a) but not vice versa
(Figure 3b), although a potential GFI1 binding site was
detected in the STAT3 promoter but not in PTGER2
(Figure 3c). Chromatin immunoprecipitation (ChIP) assays
confirmed less and less GFI1 bound to the endogenous
STAT3 promoter during LSMCM stimulation (Figure 3d). GFI1
expression significantly decreased phosphorylated and total
STAT3 (Figure 3e). Luciferase reporter assays revealed
specific binding between GFI1 and the indicated sequence
(Figure 3c) in the STAT3 promoter (Figure 3f). Furthermore,
STAT3 siRNA treatment moderately reduced EP2 protein
expression (Figure 3g) but not its mRNA expression
(Supplementary Figure S4A). Conversely, PTGER2 siRNA
treatment did not affect STAT3 expression or activation by
LSMCM (Figure 3h, Supplementary Figure S4B). We subse-
quently detected the physical interaction between STAT3 and
EP2, which was further enhanced after LSMCM treatment
(Figure 3i, Supplementary Figure S4C), but not transcri-
ptional regulation of STAT3 on PTGER2 (Supplementary
Figure S4D). Thus, the GFI1-STAT3-EP2 signalling cascade
is activated in HT29 cells under LSMCM stimulation.
Moreover, although GFI1-expressing cells showed
decreased ERK1/2 phosphorylation (Figure 3j), ERK1/2
siRNA, or U0126 (an MEK inhibitor) treatment reduced EP2
expression at the protein level (Figure 3k, Supplementary
Figure S4E) but not mRNA (Supplementary Figure S4F).
However, PTGER2 siRNA had no effect on ERK1/2 phos-
phorylation (Figure 3l). In addition, we observed physical
interactions between ERK1/2 and EP2 (Figure 3m). These
data suggest that, similar to STAT3, ERK1/2 activation upon
GFI1 reduction contributed to increased EP2 expression. In
response to LSMCM treatment, the activation of AKTand p65
was observed later than EP2 upregulation (Figure 2d).
PTGER2 siRNA treatment reduced both AKT and p65
phosphorylation (Figure 3n). Furthermore, the inhibition of
AKT phosphorylation using Ly294002 reduced p65 phosphor-
ylation; RELA (coding for p65) siRNA, or PDTC (an inhibitor of
NF-κB activation) had only a minor effect on AKT phosphory-
lation (Figure 3o, Supplementary Figure S4G). These data
suggest the existence of an EP2-AKT-NF-κB cascade.
GFI1 downregulation enhances the metastasis of human
CRC cells. To determine whether the activation of signalling
effectors affects the consequent production of cytokines, we
examined expressions of 10 cytokines in HT29 cells
incubated in LSMCM for 24 h. The results showed that,
except for IFNγ (data not shown), the mRNA expression of
GM-CSF, IL8, MCP1, PDGFBB, sTNFR1, TGFβ1, IL1α, I309,
and TNFβ significantly increased (Figure 4a). Moreover,
ELISA showed a significant decrease in TGFβ production at
6 h and a return to basal amounts at 24 h after LMSCM
addition (Figure 4b), consistent with previous data
(Figure 2a). We next applied shRNA, siRNA or gene
overexpression to GFI1, PTGER2, STAT3, or RELA in the
cell model. The results showed that forced GFI1 expression
suppressed all 9 cytokines at the mRNA level, but GFI1
knockdown induced the expression of these molecules;
PTGER2 siRNA had only moderate inhibition effects. In
comparison, gene knockdown of STAT3 or RELA had
variable effects, inhibiting the expression of certain cytokines
while increasing others (Figure 4c). Collectively, the most
consistent effect of LSMCM incubation was the repression of
GFI1, which acts as a suppressor of cytokine gene
expression. The effect of decreased GFI1 may be mediated
via STAT3 and ERK1/2, which stimulate EP2 expression
(Figure 4d).
Moreover, GFI1 overexpression in LMSCM-stimulated
HT29 cells reversed the changes in the expression of EMT
markers and greatly inhibited cell migration and invasion
(Figure 4e and f); conversely, GFI1 knockdown significantly
enhanced cell migration & invasion, induced EMT (Figure 4g
and h), and increased EP2 expression and STAT3, p65, AKT,
and ERK phosphorylation (Supplementary Figure S4H).
Keeping consistent, we further showed that although SW480
cells exhibited the weakest response and SW620 cells
exhibited the strongest response to LSMCM stimulation, the
expression of GFI1 was the highest in SW480 cells and lowest
in SW620 cells among the tested CRC cells (Figure 5a and b).
In parallel, forced GFI1 expression in SW620 cells signifi-
cantly reduced cell migration and invasion and vice versa
(Figure 5c–f). Whereas SW620 cells poorly responded to
LSMCM stimulation (Figure 1a, j and k), forced GFI1
expression greatly enhanced SW620 sensitivity to LSMCM
(Figure 5g). Collectively, these data indicated an essential role
for GFI1 downregulation in coordinating the changes in the cell
behaviour and metastatic potential of CRC cells.
GFI1/Gfi1 inhibits CRC metastasis to distal sites. We
further examined GFI1 effect in vivo. GFI1 overexpression
and control HT29 cells incubated with LMSCM for 24 h
were subcutaneously (s.c.) transplanted into DKO (BALB/c-
Rag2−/−gc−/−) mice, and the s.c. tumour masses were
harvested. The tumour growth rates, volume and mouse
body weight were similar between the two groups of animals
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before and after tumour cell transplantation (Supplementary
Figure S5A-E). Immunoblot analysis confirmed GFI1 over-
expression and the decreased expression of STAT3, Snail,
and Zeb1 in GFI1-positive tumours in vivo (Supplementary
Figure S5F).
Next, we injected cultured GFI1-expressing (GFI1-T) and
NC-T s.c. tumour cells via the tail vein (t.v.) into DKO mice
(Supplementary Figure S5G). LSMCM stimulation for 24 h
prior to tumour cell injection greatly accelerated lung
metastasis in the NC-T group, reducing latency from 90 to
30 d compared with cells not subjected to LSMCM stimulation
(data not shown). Moreover, significantly more lung metas-
tases were observed in the NC-T than GFI1-T group at 30 d
(Supplementary Figure S5H, I). Furthermore, at 60 d, all eight
NC-T mice and only one of the eight GFI1-T mice showed lung
metastases, whereas three out of eight NC-T and no GFI1-T
mice showed secondary metastasis to the liver, with
significantly larger metastases in the lungs of NC-T mice
(Supplementary Figure S6A-F). In addition, NC-T
mice exhibited more weight loss compared with GFI1-T mice
(Supplementary Figure S6G). H&E staining of the lung
biopsies showed that the NC-T mice had more macroscopic
tumours than GFI1-T mice; and NC-T liver metastases were
also large (Supplementary Figure S6B, E).
To further investigate the role of murine Gfi1 in CRC cell
metastasis in immune competent mice, we constructedMC38-
Gfi1 andMC38-con cell lines using CRISPR/Cas9 technology.
Forced Gfi1 activation in metastatic MC38 CRC cells reduced
the rates of cell migration and invasion, diminished the
expressions of EP2 and STAT3, and attenuated STAT3, AKT,
and p65 phosphorylation (Figure 6a and b). We next
intrasplenically (i.s.) injected these cells into syngeneic
C57BL/6 mice and subsequently examined liver metastases
and disease progression. Gfi1 overexpression greatly reduced
tumour metastatic incidence (Supplementary Figure S6H),
liver metastases sizes and body weight in age-matched
groups (Figure 6c–f). In addition, MC38-Gfi1 mice survived
much longer than the control mice (Figure 6g).
GFI1 downregulation increased the metastatic ability
of CRC cells in vivo. HT29 cells harbouring GFI1 gene
knockdown by shRNA or control plasmid were s.c. trans-
planted into nude mice and harvested at 20 d. The results
showed no significant differences between the two groups of
mice in animal body weight, tumour formation rate, and
tumour weight and volume (Supplementary Figure S7A–E),
although shGFI1 tumours seemed smaller than the controls
(Supplementary Figure S7C, D). Next, we injected these two
groups of cells via the t.v. into the mice. At 40 d after injection,
all of the lungs from the shGFI1 mice and none of the lungs
from control mice developed pronounced lung metastases
(Supplementary Figure S7F, G). GFI1 knockdown had a
minor effect on the body weight of the mice; H&E staining
revealed that the lungs from shGFI1 mice showed aggre-
gated CRC cells around the blood vessels to form larger
metastases (Supplementary Figure S7H, I).
To determine whether GFI1 downregulation correlated with
CRCmetastatic progression in humans, we analysed a TCGA
data set including 155 patient biopsies from primary tumour
sites. The results indicated that the primary tumours from
patientswithmetastatic CRC (M1) expressed significantly less
GFI1 than those from patients who did not progress to
metastatic disease (M0) (Figure 6h). Collectively, these data
strongly suggest that GFI1 downregulation promotes CRC
metastasis to distant organs.
Loss of GFI1 in advanced human CRC samples. To
further relate GFI1 expression with CRC metastasis, we
examined a series of human biopsies, including normal colon
tissues (n=10), cancer adjacent normal colonic tissue
(n=10), precancerous colon lesions (n=5 adenomatous
and n= 5 polyp tissues), CRC (n=23) and CRC metastatic
lesions (n=23) using IHC (Figure 7a). The loss of GFI1
expression was primarily observed in advanced CRC (stage
IIB and higher) and metastases compared with normal and
lower stage tissues, respectively (Figure 7b and c).
Decreased GFI1 expression was initially observed at stage
IIB and further decreased at stage III (Figure 7a), suggesting
that GFI1 dowregulation likely precedes metastatic spread. In
addition, in the same set of human samples, the markedly
increased expression of STAT3 was observed in CRC
compared with normal biopsies (Supplementary Figure
S8A, B), although the expression was similar between early-
and late-stage tumour samples (Supplementary Figure S8C).
Moreover, a negative correlation between GFI1 and STAT3
expression at the protein level was observed across all
categorised sample sets, and significantly correlated expres-
sion was only observed in normal colon specimens and
metastases (Supplementary Figure S8D). These data
Figure 3 GFI1 is a gating regulator that controls CRC cell metastatic activity. (a) qRT-PCR of PTGER2 mRNA in HT29 cells transfected with GFI1-encoding or control
plasmid. (b) qRT-PCR of GFI1 mRNA in HT29 cells treated with PTGER2 siRNA or NC. (c) Analysis of GFI1 binding sites in PTGER2 or STAT3 promoters. (d) ChIP assays of
GFI1 recruitment to the STAT3 promoter in HT29 cells incubated with LSMCM for up to 96 h. The data are presented as enrichment of precipitated DNA from chromatin incubated
with an anti-GFI1 antibody versus IgG. (e) GFI1 and STAT3 expression and phosphorylation in HT29 cell transfected with control or GFI1-encoding plasmids. (f) Luciferase assays
measuring GFI1 -repressive activity in HT29 cells transfected with STAT3 promoter (WT) or (mutant)-luc plasmid. (g) EP2 and STAT3 protein expression and phosphorylation in
HT29 cells treated with control or STAT3 siRNA. (h) STAT3 expression and phosphorylation in HT29 cells treated with PTGER2 or control siRNA. (i) Co-IP assays of STAT3
binding to EP2 in HT29 cells treated with or without LSMCM. Data are presented as enrichment of precipitated protein from whole-cell lysates immunoprecipitation with an
anti-EP2 antibody or non-specific IgG. (j) Total and phosphorylated ERK1/2 levels in HT29 cells transfected with the GFI1-encoding plasmid or control. (k) EP2, ERK1/2, and
phosphor-ERK1/2 expression in HT29 cells pretreated with MAPK1/3 siRNA or control. (l) ERK1/2 phosphorylation in HT29 cells treated with PTGER2 siRNA or control. (m)
Co-IP assays of ERK1/2 binding to EP2 in HT29 cells treated with or without LSMCM. (n) AKTand p65 phosphorylation in HT29 cells transfected with control (NC) or PTGER2
siRNA with or without LSMCM. (o) AKTand p65 phosphorylation in HT29 cells pretreated with or without 20 μM PI3K inhibitor (Ly294002) or RELA siRNA for 12 h, followed by
treatment with LSMCM or LSMCM plus respective inhibitors or siRNA for 24 h. Results in (a), (b), and (f) are shown as means± S.D. of three independent experiments.
Statistically significant differences are indicated. *Po0.05; **Po0.01
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Figure 4 GFI1 controls an inflammatory signalling circuit that enhances invasive and migratory behaviour of human CRC Cells. (a) qRT-PCR of indicated cytokine mRNA in
HT29 cells incubated with control medium or LSMCM for 24 h. (b) TGFβ concentrations by ELISA assays in supernatants from HT29 cells that were treated with LSMCM for the
indicated periods. (c) qRT-PCR of shown cytokine mRNA in HT29 cells treated with LSMCM or LSMCM with the indicated shRNAs, siRNAs, or GFI1-expressing plasmids. (d)
Schematic overview of the inflammation and TGFβ-induced regulatory circuit that controls CRC cell metastatic behaviour. (e) qRT-PCR of E-cadherin, Fibronectin, and
Vimentin mRNA in HT29 cells transfected with GFI1-encoding plasmid or control. (f) Regulation of HT29 invasive and migratory behaviour by ectopically expressed GFI1. (g)
Regulation of HT29 invasive and migratory behaviour by knocking down of GFI1 expression. (h) qRT-PCR of E-cadherin, Fibronectin and Vimentin mRNA in HT29 cells
transfected with GFI1 shRNA or control. (a–c), (e–h) are shown as means± S.D. of three independent experiments. Statistically significant differences are indicated. *Po0.05;
**Po0.01
Figure 5 GFI1 controls invasive and metastatic behaviour of CRC cells. (a) Invasive and migratory activity of different CRC cell lines (SW480, HT29, LoVo, SW620). (b) qRT-
PCR of GFI1 mRNA in three other human CRC cells shown relative to GFI1 mRNA content of HT29 cells. (c) GFI1 protein expression in SW620 cells transfected with
GFI1-encoding plasmid or control. (d) GFI1 protein expression in SW480 cells transfected with GFI1 shRNA plasmid or control. (e) Migratory and invasive behaviour of SW620
cells transfected with negative control or GFI1-encoding plasmids or control. (f) Migratory and invasive behaviour of SW480 cells transfected with negative control or GFI1 shRNA
plasmids or control. (g) Migratory and invasive behaviour of SW620 cells transfected with negative control or GFI1-encoding plasmids upon LSMCM stimuli. (b), (e–g) are shown
as means± S.D. of three independent experiments. Statistically significant differences are indicated. *Po0.05; **Po0.01
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Figure 6 Gfi1 inhibits MC38 metastasis to liver. (a) Migratory and invasive activity of MC38 cells transfected with control or Gfi1-activation plasmids. (b) Immunoblot analysis
of MC38-con and MC38-Gfi1 cells demonstrating effects of Gfi1 on indicated signalling proteins. (c) Liver metastases in mice injected intrasplenicly (i.s.) with MC38-con or
MC38-Gfi1 cells. Arrows pointed to metastases in the liver. (d) Representative H&E-stained sections of the livers of mice injected with MC38-Gfi1 or MC38-con cells. (e) Weights
of livers in mice injected with MC38-Gfi1 or MC38-con cells 16 days after i.s. injection. (f) Weight of mice injected with MC38-Gfi1 or MC38-con cells 16 days after i.s. injection. (g)
Kaplan–Meier survival curve in respective MC38-Gfi1 and -con mice, log-rank test, Po0.0001. (h) GFI1 expression levels in the primary tumour of human CRC in patients
who did (M1) or did not (M0) develop distal metastases in a TCGA data set
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suggest that GFI1 downregulation may be highly correlated
with increased STAT3 expression in CRC human samples.
To confirm the role of GFI1 in an even larger number of
clinical samples, we examined the public databases of colon
cancer data sets, including CRC data from TCGA, GSE17538,
GSE41258, and GSE14333, comprising a total of 918 clinical
samples. Notably, a significant decrease in GFI1 expression
was observed in advanced CRC relative to early-stage
tumours (Figure 7d). To evaluate the clinical prognosis value
of GFI1 expression, we used another set of CRC data
containing 177 samples harbouring relapse-free survival time
(GSE39582). By stratifying cancer patients according to GFI1
mRNA expression (median), we observed that lower GFI1
mRNA expression was associated with decreased patient
survival (Figure 7e). Interestingly, a significant GFI1 loss was
also observed in adenomas and polyps compared with normal
tissues (Figure 7f), suggesting that this loss might be an early
event in colon carcinogenesis that needs to exceed a certain
threshold to enable cancer cells to acquire metastatic
properties.
Discussion
Cancer metastasis is a multi-step process relying on tumour–
stroma interactions. Inflammation greatly contributes to CRC
development and progression.20,35,36 In the present study, we
identified an inflammatory environment-mediated transcrip-
tional programme that controls themetastatic potential of CRC
through GFI1, a transcriptional repressor. Curiously, a key
cytokine responsible for GFI1 downregulation is TGFβ.
Although in early CRC cells and premalignant lesions,
the TGFβ signalling pathway has tumour-suppressive
activities,37–39 the pro-metastatic activity of this signalling
pathway is observed in more advanced cancer.40,41 These
results suggest that tumour stromal cytokinesmay accomplish
pro-metastatic activity through GFI1. Importantly, the analysis
of human clinical specimens confirmed that GFI1 down-
regulation correlated with increased CRC metastasis.
Previously, GFI1 demonstrated importance in the lineage
decision process during IEC differentiation,30,31 but the results
of the present study are the first to implicateGFI1 as a negative
regulator of CRC metastasis. GFI1 downregulation during the
metastatic progression of CRC may reflect increased TGFβ1
expression in TGFβR- and SMAD2/3-expressing CRC cells.42
In addition, using a cell model of inflammation-driven
metastasis, we verified that other cytokines, such as IL1α,
TNFβ or IFNγ in the tumour microenvironment also contributed
to GFI1 decrease, thereby activating CRC cell metastatic
behaviours; yet the effect of the cytokine combination or other
factors needs further verification. Consistently, some of these
cytokines, or conditioned medium from TAMs, were implicated
in EMT-like processes and promoting metastatic behaviours in
CRC cells.43–47 Moreover, NF-κB and/or STAT3 signalling and
the feed-forward activation circuit in CRC cells may support
metastasis to remote organs.48–50
STAT3 has been demonstrated as an important player in
inflammation-associated CRC progression.15,51,52 Our data
highlight STAT3 as a core TF in the inflammation-mediated TF
network that controls CRC metastasis and showed that GFI1
expression inhibits STAT3 activation. Previous studies showed
that GFI1 enhanced STAT3 activation through interactionswith
the STAT3 inhibitor PIAS3.29 In contrast, the results of the
present study showed that although GFI1 controlled STAT3
transcription through binding to its promoter, GFI1 down-
regulation triggered via LMSCMabrogated the effect, resulting
in STAT3 activation. This variation suggests the operation of a
context-dependent regulatory circuit. Consistent with other
data,41,53–55 we verified that EP2 signalling activation was
highly relevant to inflammation-associated CRC progression.
It has been suggested that disseminated cancer cells are
selected via stroma–tumour interactions before adapting to
new microenvironmental conditions and giving rise to a
metastatic clone.38,56 There is a debate as to whether this
selection occurs within or outside the primary tumour.57 We
observed that once GFI1 downregulation within CRC cells
reaches a certain threshold, CRC cells become competent for
metastatic spread as a result of the long-term activation of a
regulatory circuit that is normally repressed by GFI1. The
ectopic overexpression of GFI1/Gfi1 impaired the function of
this signalling circuit and inhibited the metastatic activity of
CRC cells, and vice versa. Although we observed that GFI1
expression is lost in humanmetastatic CRC and confirmed the
ability of GFI1 to suppress metastatic spread, the CRC
metastasis process is complex and likely to involve additional
regulation.20,58 For example, despite a strongly reverse
relationship between GFI1 and STAT3 expression in normal
human colorectal tissue samples, such a relationship was less
pronounced in CRC samples (Supplementary Fig S8D and
data not shown). As a gating regulator of CRC metastasis,
GFI1 downregulation may elicit further feedback and/or
network regulations on its downstream effectors, such as
STAT3, besides other layers of disease complexity
(Supplementary Figure S6I). Thus far, the dynamics of cellular
adaptation resulting from genetic/epigenetic changes or
phenotypic plasticity remain poorly understood in patients
with advanced cancer.59
In summary, these findings elucidate a new mechanism
contributing to the acquisition of metastatic potential during
CRC progression. Therapeutic interventions that restore GFI1
expression may be suitable for the treatment of metastatic
CRC, a condition that conveys high rates of mortality.
Materials and Methods
Cell culture, transfection, and treatment. THP1, U-937, HT29, LoVo,
SW480, and SW620 cells from ATCC and MC38 cells granted from Dr. Shoshana
Yakar were cultured at 37 °C and 5% CO2 in Dulbecco’s modified Eagle’s medium
or RPMI 1640 medium (Hyclone, Foster City, CA, USA) supplemented with 10%
fetal bovine serum (FBS). Human cells were transfected using lipofectamine
(Invitrogen, Grand Island, NY, USA). LSMCM were prepared from the supernatants
of human THP1 cells mock stimulated or stimulated with Salmonella enteritidis-
derived LPS (Sigma-Aldrich, St Louis, MO, USA) for 6 h. THP1 cells subsequently
were centrifuged, and the supernatant was filtrated to eliminate any remaining cells.
PBMC were isolated from human blood using lymphocyte separation solution, and
then were induced into macrophage via IL4 and IL10 stimulation. U-937 cells also
pretreated as PBMC. LSMφM were prepared like LSMCM using macrophages
derived from PBMC or U-937 cells. CRC cells then were cultivated in the presence
of regular medium or half LSMCM or LSMφM and half regular medium. Where
indicated, cells were treated with anti-TGFβ neutralising antibody (Raybiotech,
Norcross, GA, USA), 10 μM of U0126, 20 μM of Ly294002 or 10 μM of PDTC
(Sigma-Aldrich) for the indicated times.
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Construction of MC38-Gfi1 cells with CRISPR activation plas-
mids. To generate MC38-Gfi1 and -con cells, we used CRISPR Gfi1-activation
plasmid (sc-437272) and control CRISPR/Cas9 plasmid (sc-418922, Santa Cruz
Ltd., Dallas, CA, USA). Gfi1 CRISPR Activation Plasmid is a synergistic activation
mediator transcription activation system designed to specifically upregulate gene
expression according to manufacturer’s instructions (Santa Cruz Ltd.). In brief, we
infected MC38 cells with three plasmids at a 1:1:1 mass ratio: a plasmid encoding
the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the
transactivation domain VP64, and a blasticidin-resistant gene; a plasmid encoding
the MS2-p65-HSF1 fusion protein, and a hygromycin-resistant gene; a plasmid
encoding a target-specific 20 nt guide RNA (gRNA), and a puromycin-resistant
gene. The positive cells were selected and cultured. Similar procedures were
applied to generate MC38-con cells using control CRISPR activation plasmid.
Real-time PCR analysis. Total RNA was extracted using TRIzol (invitrogen).
RNA was reverse transcribed using a Reverse Transcription kit (Applied Biosystems,
Foster city, CA, USA). Real-time PCR was performed using SYBR green (Roche,
Mannheim, Germany) on a Step One Real-time PCR System (Applied Biosystems).
Expression data were normalised to GAPDH mRNA expression. Data were
calculated as 2-ΔΔCt. Primer sequences are listed in Supplementary information.
ELISA and human antibody cytokine arrays. Culture medium was
collected and subjected to ELISA analysis. Human TGFβ1 and TGFβ2
concentration were measured by ELISA (Raybiotech) according to the
manufacturer’s protocols. Measurement and analysis of Antibody Cytokine Arrays
for 40 kinds of cytokines associated with macrophage were provided by Raybiotech.
Luciferase reporter assays. The pGL3-STAT3 or pGL3-STAT3-mut (BOSHI
Ltd., Harbin, China) was transfected into HT29, HT29-NC, and HT29-GFI1 cells
using lipofectamine 2000 (Invitrogen). Luciferase activity was measured 48 h after
transfection.
Migration and invasion assays. About 4000 cells were seeded into the
upper chambers in 100 μl of the culture medium containing 1% FBS. Transmigration
of cells into the lower compartment containing 600 μl medium (9% FBS) occurred at
37 °C. After 24 h, transwells were removed and cleaned with cotton swabs to
remove non-migrated cells. Migrated cells adherent to the bottom of the membrane
were stained with crystal violet (Sigma-Aldrich). Each determination was done at
least in duplicates. Data are expressed as the number of migrating cells per field.
For invasion assays, the upper chambers were coated with matrigel before using
and the procedures were as above.
For monolayer wound-healing assays, a total of 3 × 105 cells were collected and
plated in a six-well plate. At 100% confluence, two parallel wounds of 1 mm were
made using a pipette tip. The number of cells crawling into the wound was measured
after 24 h, in three independent experiments.
Chromatin immunoprecipitation. Cells were cross-linked with 1%
formaldehyde at room temperature for 10 min, washed twice with 10 ml ice-cold
PBS, and then scraped into 0.5 ml of lysis buffer and left on ice for 10 min. Samples
were treated according to the instructions of ChIP kit (Beyotime, Haimen, Jiangsu,
China). Immunoprecipitations were performed overnight with GFI1 antibody (1–
2 μg). Immune-complexes were captured by incubation with 40 μl protein A/G
Sepharose. DNA extraction was performed using Qiagen Purification Kit. The
samples were analysed by PCR using primers whose sequences are listed below.
STAT3 promoter-F: gggttagctgagcagtgacat
STAT3 promoter-R: aagctgataacgtgtagggct
PTGER2 promoter-F: gcgcattgtgtggtttggtt
PTGER2 promoter-R: acacagaagatcggggcaac
Animals. The DKO mice studies were approved by the Infection and Immunity
Center of Chinese Academy of Sciences. DKO (BALB/c-Rag2−/−gc−/−) mice were
kindly provided by Professor Lieping Chen, Department of Immunology, Yale
University School of Medicine, New Haven USA and used at age of 8–12 weeks.
The mice were maintained under specific pathogen-free conditions in the animal
facility at the Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
The female C57BL/6 mice were purchased from YISI Laboratory Animal Technology
Co., Ltd. (Changchun, China) and used at 10-week-old. The female nude mice were
purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing,
China) and used at 6-week-old. These mice were maintained under specific
pathogen-free conditions in Infection Key Laboratory of Heilongjiang Province,
Harbin, China.
Xenograft experiments. Approximately 1 × 107 HT29-NC and HT29-GFI1
cells pretreated with/without LSMCM for 24 h; or HT29-vector and HT29-shGFI1
cells were s.c. injected into the right flank of DKO or nude mice. Tumour growth was
monitored every three days and tumour volumes were calculated by the equation V
(mm3)= a × b2/2, where a is the largest diameter and b is the perpendicular
diameter.
Mouse in vivo metastasis studies. For in vivo metastasis assays, six-
week-old DKO or nude mice were housed in a specific pathogen-free facility. In total,
7 × 106 human CRC cells were suspend in 100 μl culture medium and injected via
the t.v. Mice were monitored every three days and body weights were measured.
After 30, 40, or 60 d, mice were killed, and lungs and livers were collected and the
metastases were counted and analysed, respectively.
For CRC liver metastasis models, 1 × 106 MC38 or MC38-Gfi1 cells were
suspended in 100 μl culture medium and injected into spleen of 10-week-old C57BL/
6 females. Part of animals were killed 16 d after cell injection and analysed.60
Pathological changes were detected by H&E staining on the liver. The survival curves
of the other part animals were analysed until 50 d or longer by GraphPad Prism
Software.
Statistical analysis. Statistical analyses were performed using the GraphPad
Prism Software. D’Agostino & Pearson normality test was performed prior to
statistical analysis. For comparisons, Student’s t-test (two-tailed) was used when
normality test was achieved. Non-parametric test Mann–Whitney U-test was
performed when normality test failed, Log-rank (Mantel–Cox) test was used for
survival analysis, Pearson's correlation test was used to evaluate the expression
relationships. A Po0.05 was considered significant.
Accession numbers. The mRNA expression data (TCGA, GSE17538,
GSE41258, GSE14333 and GSE39582).
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